Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included newly diagnosed women with HER2-positive invasive breast cancer due to undergo surgery. Patients were randomized to: part 1 (1:2:2), no treatment (control), trastuzumab or lapatinib; part 2 (1:1:2) control, trastuzumab, or lapatinib and trastuzumab combination. Treatment was given for 11 days presurgery. Coprimary endpoints were change in Ki67 and apoptosis between baseline and surgery tumor samples (biologic response: ≥30% change). Central pathology review scored residual cancer burden (RCB). Relapse-free survival (RFS) explored long-term effects. Results: Between November 2010 and September 2015, 257 patients were randomized (part 1: control 22, trastuzumab 57, lapatinib 51; part 2: control 29, trastuzumab 32, combination 66). Ki67 response was evaluable for 223 patients: in part 1 Ki67 response occurred in 29/44 (66%) lapatinib versus 18/49 (37%) trastuzumab (P = 0.007) and 1/22 (5%) control (P < 0.0001); in part 2 in 36/49 (74%) combination versus 14/31 (45%) trastuzumab (P = 0.02) and 2/28 (7%) control (P < 0.0001). No significant increase in apoptosis after 11 days was seen in treatment groups. Six patients achieved complete pathologic response (pCR, RCB0) and 13 RCB1, all but two in the combination group. After 6 years median follow-up, 28 (11%) had recurrence and 19 (7%) died. No recurrences or deaths were observed among patients who achieved a pCR. Ki67% falls ≥50% associated with fewer recurrences (P = 0.002). Conclusions: Early response after short duration anti-HER2 dual therapy identifies cancers dependent on the HER2 pathway providing a strategy for exploring risk-adapted individualized treatment de-escalation.
1323-1334
Bundred, N
729b2429-856a-43c9-b65f-3dcb2b1db904
Porta, N
7a23ffe6-b75e-42b7-86c6-85b1a49153ba
Murray Brunt, A
077a95e9-654c-4c1a-a2ad-0401766a16e7
Cramer, A
9df30203-c41f-42f0-aff7-c0887b6d579c
Hanby, A
24951643-519c-4bc8-ae3c-60843bf3da1a
Shaaban, A M
11b60529-2080-4dd3-9b35-62ea0f214eec
Rakha, E A
def6224c-aa11-44ef-bda2-569ea23aa5e8
Armstrong, A
9f79b701-5501-4e07-a2d6-5d83cc0fdb34
Cutress, Ramsey
68ae4f86-e8cf-411f-a335-cdba51797406
Dodwell, D
ff297c15-b1b2-44ea-8137-112ecdf8ddeb
Emson, M A
863e97e2-b93a-4bb9-a3c7-5fd797cfa163
Evans, A
6fdd6a25-cb21-40ed-ba7c-26d4b64383cc
Hartup, S M
bcf0bb6b-36fc-4d85-982c-dc7df47affa2
Horgan, K
4241c0a3-ded1-4ce3-9e49-166e5a20f39c
Miller, S E
9be3d620-5541-41e5-9c7c-2a378a68ec41
McIntosh, S A
ecefb5c6-401e-4447-9eff-3da20e80218e
Morden, J P
42200005-e381-4fe0-8713-4e8b2e151788
Naik, J
82d68e8d-41e0-4bf6-8925-75c6c8ff02bb
Narayanan, S
915a526d-f338-4cc1-a985-901efb540731
Ooi, J
90d9c52b-b215-4881-9690-aa31897cb3e0
Skene, A I
8444be27-f542-4a28-bf4d-9428a8adbcaa
Cameron, D A
44b50a0b-eb68-42f7-b0bc-3eac7dae65a3
Bliss, J M
b6c0190e-c188-436e-829d-d3828fff2876
1 April 2022
Bundred, N
729b2429-856a-43c9-b65f-3dcb2b1db904
Porta, N
7a23ffe6-b75e-42b7-86c6-85b1a49153ba
Murray Brunt, A
077a95e9-654c-4c1a-a2ad-0401766a16e7
Cramer, A
9df30203-c41f-42f0-aff7-c0887b6d579c
Hanby, A
24951643-519c-4bc8-ae3c-60843bf3da1a
Shaaban, A M
11b60529-2080-4dd3-9b35-62ea0f214eec
Rakha, E A
def6224c-aa11-44ef-bda2-569ea23aa5e8
Armstrong, A
9f79b701-5501-4e07-a2d6-5d83cc0fdb34
Cutress, Ramsey
68ae4f86-e8cf-411f-a335-cdba51797406
Dodwell, D
ff297c15-b1b2-44ea-8137-112ecdf8ddeb
Emson, M A
863e97e2-b93a-4bb9-a3c7-5fd797cfa163
Evans, A
6fdd6a25-cb21-40ed-ba7c-26d4b64383cc
Hartup, S M
bcf0bb6b-36fc-4d85-982c-dc7df47affa2
Horgan, K
4241c0a3-ded1-4ce3-9e49-166e5a20f39c
Miller, S E
9be3d620-5541-41e5-9c7c-2a378a68ec41
McIntosh, S A
ecefb5c6-401e-4447-9eff-3da20e80218e
Morden, J P
42200005-e381-4fe0-8713-4e8b2e151788
Naik, J
82d68e8d-41e0-4bf6-8925-75c6c8ff02bb
Narayanan, S
915a526d-f338-4cc1-a985-901efb540731
Ooi, J
90d9c52b-b215-4881-9690-aa31897cb3e0
Skene, A I
8444be27-f542-4a28-bf4d-9428a8adbcaa
Cameron, D A
44b50a0b-eb68-42f7-b0bc-3eac7dae65a3
Bliss, J M
b6c0190e-c188-436e-829d-d3828fff2876
Bundred, N, Porta, N, Murray Brunt, A, Cramer, A, Hanby, A, Shaaban, A M, Rakha, E A, Armstrong, A, Cutress, Ramsey, Dodwell, D, Emson, M A, Evans, A, Hartup, S M, Horgan, K, Miller, S E, McIntosh, S A, Morden, J P, Naik, J, Narayanan, S, Ooi, J, Skene, A I, Cameron, D A and Bliss, J M
(2022)
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Clinical Cancer Research, 28 (7), .
(doi:10.1158/1078-0432.CCR-21-3177).
Abstract
Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included newly diagnosed women with HER2-positive invasive breast cancer due to undergo surgery. Patients were randomized to: part 1 (1:2:2), no treatment (control), trastuzumab or lapatinib; part 2 (1:1:2) control, trastuzumab, or lapatinib and trastuzumab combination. Treatment was given for 11 days presurgery. Coprimary endpoints were change in Ki67 and apoptosis between baseline and surgery tumor samples (biologic response: ≥30% change). Central pathology review scored residual cancer burden (RCB). Relapse-free survival (RFS) explored long-term effects. Results: Between November 2010 and September 2015, 257 patients were randomized (part 1: control 22, trastuzumab 57, lapatinib 51; part 2: control 29, trastuzumab 32, combination 66). Ki67 response was evaluable for 223 patients: in part 1 Ki67 response occurred in 29/44 (66%) lapatinib versus 18/49 (37%) trastuzumab (P = 0.007) and 1/22 (5%) control (P < 0.0001); in part 2 in 36/49 (74%) combination versus 14/31 (45%) trastuzumab (P = 0.02) and 2/28 (7%) control (P < 0.0001). No significant increase in apoptosis after 11 days was seen in treatment groups. Six patients achieved complete pathologic response (pCR, RCB0) and 13 RCB1, all but two in the combination group. After 6 years median follow-up, 28 (11%) had recurrence and 19 (7%) died. No recurrences or deaths were observed among patients who achieved a pCR. Ki67% falls ≥50% associated with fewer recurrences (P = 0.002). Conclusions: Early response after short duration anti-HER2 dual therapy identifies cancers dependent on the HER2 pathway providing a strategy for exploring risk-adapted individualized treatment de-escalation.
Text
CCR-21-3177R2_Merged_PDF
- Accepted Manuscript
Text
ccr-21-3177
- Version of Record
More information
Accepted/In Press date: 20 January 2022
Published date: 1 April 2022
Additional Information:
We thank all participating patients and their families, involved staff at participating hospitals, and staff involved in the trial at The Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU). The trial was funded by Cancer Research UK with approval of its design from their Clinical Trials Awards and Advisory Committee (CRUK/08/002). ICR-CTSU receives programme grant funding from Cancer Research UK (grant Nos. C1491/A9895, C1491/A15955, C1491/A25351). Lapatinib was provided to centers by Novartis (formerly GlaxoSmithKline), who also supplied an educational grant. None of the funders had a direct role in study design, data collection, data analysis, data interpretation, or writing of the report.
The EPHOS-B trial represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We acknowledge support at participating sites by the NIHR Cancer Research Network (CRN)/NHS Research Scotland/Health and Care Research Wales.
Identifiers
Local EPrints ID: 455120
URI: http://eprints.soton.ac.uk/id/eprint/455120
ISSN: 1078-0432
PURE UUID: 51bb064b-22be-439a-a5ca-bde7c5e32a2c
Catalogue record
Date deposited: 10 Mar 2022 17:31
Last modified: 17 Mar 2024 07:09
Export record
Altmetrics
Contributors
Author:
N Bundred
Author:
N Porta
Author:
A Murray Brunt
Author:
A Cramer
Author:
A Hanby
Author:
A M Shaaban
Author:
E A Rakha
Author:
A Armstrong
Author:
D Dodwell
Author:
M A Emson
Author:
A Evans
Author:
S M Hartup
Author:
K Horgan
Author:
S E Miller
Author:
S A McIntosh
Author:
J P Morden
Author:
J Naik
Author:
S Narayanan
Author:
J Ooi
Author:
A I Skene
Author:
D A Cameron
Author:
J M Bliss
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics